Navigation Links
Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
Date:9/14/2010

g, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). Optimer has completed two Phase 3 trials of fidaxomicin for the treatment of CDI demonstrating that fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) as well as statistically superior in reducing recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Optimer has also successfully completed two Phase 3 trials of Pruvel™ a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the ability of fidaxomicin to treat CDI and address current treatment limitations, expectations regarding regulatory filings and the potential to bring fidaxomicin to the market. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
4. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
6. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
7. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
8. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
9. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
10. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... As part of its philanthropic partnership with ... Foundation funded a $3.25 million project to relocate and ... most up-to-date features and technology. , The new pharmacy ... staff members will begin moving from the current location ... days. , The current pharmacy has been using ...
(Date:5/20/2015)... Calif. , May 20, 2015 ... today presented preliminary data demonstrating the ability of ... pulmonary fibrosis (IPF) from other interstitial lung diseases ... suggest the classifier,s potential to help thousands of ... resolve ambiguity in IPF diagnosis – a frequent ...
(Date:5/20/2015)... The global genotyping market is expected to grow at ... 2015 to 2020 to reach $17.0billion in 2020. Genotyping ... development process and to provide personalized therapy, factors that ... by key manufacturers to offer advanced and innovative products ... 113 market data tables & 37 figures spread through ...
(Date:5/20/2015)...  Cypher Genomics, Inc., a leading genome informatics ... to apply Cypher,s Coral TM technology to ... response to innovative medicines. The information generated from ... access to the right medicine at the right ... and potentially inform new companion diagnostics.  ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2
... , Milwaukee, Wis. Merge ... leading medical imaging software and services company, today announced ... Advanced Visualization and Clinical Application software modules. This ... software includes customer-driven updates and features that further accelerate ...
... Brookfield, Wis. Fiserv, Inc. announced strong ... share-diluted from continuing operations for the third quarter of 2005 ... the third quarter of 2004. Processing and services revenues were ... of 2004. "We are also very excited about ...
... RedPrairie Corporation , a ... that enables business process transformation, ... of the top 20 retailers ... Performance Management to optimize their ...
Cached Biology Technology:
(Date:5/21/2015)... -- The Sync Project™ , a global collaboration ... announced a collaborative partnership with Berklee,s Institute for ... collaboration on original research, joint course development and an ... The Sync Project and BerkleeICE are exploring the launch ... 2015-2016 academic year.  The course will ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... -- Through a well-rounded UAS delegation representing private industry, government, and ... at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people from ... UAS ecosystem. "Our message is clear and ... Rich Knoll . "If you want to fly UAS, ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... in which the circulating strains of influenza showed genetic ... flu shot was found to be effective in preventing ... vaccine also prevented illnesses but was less effective. , ... infection, a University of Michigan study found. , ...
... Muscle weakness and fiber deterioration seen in muscular dystrophy ... under study for their effects against cancer, a Burnham ... on the potential use of these drugs, called histone ... muscles, thereby countering the progression of the disease, in ...
... an innovative new project being developed by Central Queensland ... around the country could soon have access to rehabilitation ... than having to travel to special outpatient clinics. , ... on-line outpatient rehabilitation service for people who have had ...
Cached Biology News:Flu shot effective against drifted influenza, nasal spray vaccine less so 2Flu shot effective against drifted influenza, nasal spray vaccine less so 3Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy 2
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... Digital shaking water bath, with a ... baths and shaking water baths with seamless, ... comfort. The bright MULTI-DISPLAY (LED) indicating up ... across the lab. Advanced MICROPROCESSOR technology with ...
... Features Provides a buffered anti-freeze environment ... , Maintains a liquid, low viscosity solution ... conjugate is necessary and sampling is convenient ... growth during long-term storage Protect enzyme ...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: